Will Zimulti make it here in the US? BD
PARIS (Reuters) Jan 04 - Drugmaker Sanofi-Aventis, the target of a lawsuit seeking class-action status filed on behalf of shareholders, on Friday vowed to fight allegations it hid the side-effects of its anti-obesity drug Acomplia.
A Sanofi-Aventis spokesman told Reuters that the company had seen the statement issued by the U.S. law firm that filed the lawsuit, Schiffrin, Barroway, Topaz & Kessler, and that it was "disputing the allegations contained in the statement and plans to vigorously defend itself".
"...the complaint alleges that the company failed to disclose material adverse data concerning Zimulti's tendency to cause a statistically significant increase in psychiatric problems, including suicidal thoughts and actions," the statement said.
On June 13 an advisory committee said the U.S. Food and Drug Administration (FDA) should reject the proposed pill, called Zimulti in the United States, because of concerns it could increase suicidal thinking and depression.
0 comments :
Post a Comment